Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

This early-phase study is testing the safety, dosing, and early effectiveness of ZL-6201, a new experimental drug, in adults with advanced sarcoma (a type of cancer affecting bone or soft tissues) or other selected solid tumors that have not responded to prior treatments. **You may be eligible if...** - You are 18 or older with an ECOG performance score of 0 or 1 (good physical function) - You have been diagnosed with advanced unresectable or metastatic sarcoma, or a selected solid tumor - You are willing to provide a tumor biopsy or archived tumor tissue sample - For sarcoma: you have received no more than 2 prior lines of treatment for metastatic disease - For other solid tumors: you have received no more than 3 prior lines of treatment - You have at least one measurable tumor lesion and adequate organ function - You test negative for HIV, hepatitis B, and hepatitis C **You may NOT be eligible if...** - You have another active cancer requiring treatment within the past 2 years - You have brain metastases causing symptoms or requiring steroids - You have previously been treated with a topoisomerase-1 inhibitor antibody-drug conjugate (ADC) - You have significant heart problems Talk to your doctor to see if this trial is right for you.